A Phase 4 interventional study of treprostinil sodium in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2013-01-07.
Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 26th largest by enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2006, is one of 9 in phase 4, and was the 6th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 3 started in 2006.
This study's enrollment of 10 is below the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
36 studies in Hypertension, Pulmonary by United Therapeutics: 4 open now, 4 under way, 2 of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 36 studies in Hypertension, Pulmonary by United Therapeutics, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2006, is one of 6 in phase 4, and was the 6th registered.
United Therapeutics’s Hypertension, Pulmonary studies by the year they started, since 1998.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among United Therapeutics’s 36 in Hypertension, Pulmonary:
This tab as a report to print or save as PDF → With an account.
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.
Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH and to improve health related quality of life (HRQOL).
Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the IV and SC routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Furthermore, since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension using the CADD legacy pump.
Participation in this study will last approximately 10 weeks. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, exercise tests and patient questionnaires. Participants will have 4 visits during the study and will spend at least 1 night in the hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: treprostinil sodium
rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
Also known as: Remodulin, Flolan
Change in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8.
Time frame: Baseline and Week 8
Change in Borg Dyspnea Score Immediately After Six Minute Walk Test From Baseline to Week 8
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).
Time frame: Baseline and Week 8
Change in World Health Organization (WHO) Functional Classification of PAH From Baseline to Week 8
Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.
Time frame: Baseline and Week 8
Change in Symptoms of Dyspnea From Baseline to Week 8
The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Symptoms of Edema From Baseline to Week 8
The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.
Time frame: Baseline to Week 8
Change in Symptoms of Orthopnea From Baseline to Week 8
The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Symptoms of Dizziness From Baseline to Week 8
The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Symptoms of Fatigue From Baseline to Week 8
The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Symptoms of Syncope From Baseline to Week 8
The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Symptoms of Chest Pain From Baseline to Week 8
The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Effectiveness Score on Treatment Satisfaction Scale From Baseline to Week 8
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
Time frame: Baseline and Week 8
Change in Side-Effects Score on Treatment Satisfaction Scale From Baseline to Week 8
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
Time frame: Baseline and Week 8
Change in Convenience Score on Treatment Satisfaction Scale From Baseline to Week 8
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
Time frame: Baseline and Week 8
Change in Global Satisfaction Score on Treatment Satisfaction Scale From Baseline to Week 8
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
Time frame: Baseline and Week 8
Change in Total Score on Quality of Life Questionnaire From Baseline to Week 8
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a health related quality of life instrument specific to PAH. The total score can range from 0 -75; the higher the score, the worse the outcome.
Time frame: Baseline and Week 8
Change in Patient Impression of Change in Symptoms of PAH From Baseline to Week 8
Subjects were asked to compare their symptoms of PAH as compared to 8 weeks prior and rate as much better, somewhat better, about the same, somewhat worse, or much worse.
Time frame: Baseline and Week 8
Change in Patient Impression of Change on Time Spent Dealing With Therapy From Baseline to Week 8
Subjects were asked to compare their previous experience with Flolan and rate how much time was spent dealing with intravenous Remodulin therapy as much less, somewhat less, about the same, somewhat more, or much more.
Time frame: Baseline and Week 8
Change in Patient Impression of Change of Satisfaction With Therapy From Baseline to Week 8
Subjects were asked to compare their previous experience with Flolan and rate satisfaction with intravenous Remodulin therapy over the past two weeks as much more satisfied, more satisfied, about the same, less satisfied, or much less satisfied.
Time frame: Baseline and Week 8
Change in Total Weekly Time Spent to Gather/Set-up Materials Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame: Baseline and Week 8
Change in Total Weekly Time Spent to Connect Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame: Baseline and Week 8
Change in Total Weekly Time Spent to Change Dressing With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame: Baseline and Week 8
Change in Total Weekly Time Spent to Prepare Drug With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame: Baseline and Week 8
Change in Total Number of Times Daily Required to Disconnect Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame: Baseline and Week 8
Change in Total Number of Times Daily Required to Check Infusion Pump With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame: Baseline and Week 8
Change in Total Number of Times Daily Infusion Pump Alarms With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
Time frame: Baseline and Week 8
Subject participated in this study between July 2007 and January 2008.
| Milestone | Treprostinil Sodium |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
| meters | Treprostinil Sodium |
|---|---|
| Change in the Distance Transversed During the 6 Minute Walk Test From Baseline to Week 8. | -2.2 ± 34.8 |
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).
| units on a scale | Treprostinil Sodium |
|---|---|
| Change in Borg Dyspnea Score Immediately After Six Minute Walk Test From Baseline to Week 8 | 1.56 ± 0.98 |
Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 11 |
| No Change | 89 |
| Worsened | 0 |
The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 22 |
| No Change | 33 |
| Worsened | 44 |
The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 22 |
| No Change | 56 |
| Worsened | 22 |
The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 22 |
| No Change | 78 |
| Worsened | 0 |
The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 11 |
| No Change | 89 |
| Worsened | 0 |
The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 22 |
| No Change | 67 |
| Worsened | 11 |
The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 100 |
| Worsened | 0 |
The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.
| percentage of participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 89 |
| Worsened | 11 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
| units on a scale | Treprostinil Sodium |
|---|---|
| Effectiveness Score at Baseline | 71.6 ± 29.2 |
| Effectiveness Score at Week 8 | 82.7 ± 23.1 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
| units on a scale | Treprostinil Sodium |
|---|---|
| Side Effects Score at Baseline | 71.5 ± 14.4 |
| Side Effects Score at Week 8 | 84.7 ± 12.1 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
| units on a scale | Treprostinil Sodium |
|---|---|
| Convenience Score at Baseline | 59.9 ± 14.4 |
| Convenience Score at Week 8 | 90.7 ± 10.8 |
The Treatment Satisfaction Questionnaire for Medication (TSQM) is a validated instrument that measures four major dimensions of patient satisfaction with medications: effectiveness, side effects, convenience, and global satisfaction. TSQM Scale scores are computed by adding the items loading on each factor. The lowest possible score is subtracted from this composite score and divided by the greatest possible score minus the lowest possible score. This provided a transformed score between 0 and 1 that should be multiplied by 100 (scale 0-100). A low score indicates low satisfaction and a high score indicates high satisfaction with treatment.
| units on a scale | Treprostinil Sodium |
|---|---|
| Global Satisfaction Score at Baseline | 84.1 ± 15.1 |
| Global Satisfaction Score at Week 8 | 92.1 ± 14.0 |
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is a health related quality of life instrument specific to PAH. The total score can range from 0 -75; the higher the score, the worse the outcome.
| units on a scale | Treprostinil Sodium |
|---|---|
| CAMPHOR score at Baseline | 18.9 ± 12.5 |
| CAMPHOR score at Week 8 | 12.9 ± 10.8 |
Subjects were asked to compare their symptoms of PAH as compared to 8 weeks prior and rate as much better, somewhat better, about the same, somewhat worse, or much worse.
| participants | Treprostinil Sodium |
|---|---|
| Much better | 5 |
| Somewhat better | 1 |
| About the same | 3 |
| Somewhat worse | 0 |
| Much worse | 0 |
Subjects were asked to compare their previous experience with Flolan and rate how much time was spent dealing with intravenous Remodulin therapy as much less, somewhat less, about the same, somewhat more, or much more.
| participants | Treprostinil Sodium |
|---|---|
| Much less | 8 |
| Somewhat Less | 0 |
| About the same | 1 |
| Somewhat more | 0 |
| Much more | 0 |
Subjects were asked to compare their previous experience with Flolan and rate satisfaction with intravenous Remodulin therapy over the past two weeks as much more satisfied, more satisfied, about the same, less satisfied, or much less satisfied.
| participants | Treprostinil Sodium |
|---|---|
| Much more satisfied | 7 |
| More satisfied | 2 |
| About the same | 0 |
| Less satisfied | 0 |
| Much less satisfied | 0 |
| minutes | Treprostinil Sodium |
|---|---|
| Time to gather/set up epoprostenol at Baseline | 34.9 ± 28.7 |
| Time to gather/set up Remodulin at Week 8 | 27.0 ± 28.7 |
| minutes | Treprostinil Sodium |
|---|---|
| Time spent to connect epoprostenol at Baseline | 23.2 ± 14.4 |
| Time spent to connect Remodulin at Week 8 | 18.7 ± 13.9 |
| minutes | Treprostinil Sodium |
|---|---|
| Time to change dressing with epoprostenol at BL | 31.4 ± 14.2 |
| Time to change dressing with Remdoluin at Wk 8 | 28.6 ± 25.8 |
| minutes | Treprostinil Sodium |
|---|---|
| Time to prepare epoprostenol at Baseline | 109.0 ± 61.0 |
| Time to prepare Remodulin at Week 8 | 47.8 ± 31.6 |
| number of times per day | Treprostinil Sodium |
|---|---|
| Disconnect pump at Baseline (epoprostenol) | 7.7 ± 5.3 |
| Disconnect pump at Wk 8 (Remodulin) | 4.1 ± 1.9 |
| number of times per day | Treprostinil Sodium |
|---|---|
| Check pump at Baseline (epoprostenol) | 19.2 ± 11.5 |
| Check pump at Week 8 (Remodulin) | 12.2 ± 8.9 |
| number of times per day | Treprostinil Sodium |
|---|---|
| Daily alarms at Baseline (epoprostenol) | 2.4 ± 3.3 |
| Daily alarms at Week 8 (Remodulin) | 0.8 ± 1.1 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treprostinil Sodium | — | 2/10 (20%) | 9/10 (90%) |
| Event | Treprostinil Sodium |
|---|---|
| GastroenteritisGastrointestinal disorders | 2/10 |
| Event | Treprostinil Sodium |
|---|---|
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/10 |
| HeadacheGeneral disorders | 2/10 |
| Restless Leg SyndromeNervous system disorders | 2/10 |
| Atrial fibrillationCardiac disorders | 1/10 |
| DiarrheaGastrointestinal disorders | 1/10 |
| Hand fractureMusculoskeletal and connective tissue disorders | 1/10 |
| Injection site erythemaSkin and subcutaneous tissue disorders | 1/10 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/10 |
| NauseaGastrointestinal disorders | 1/10 |
| Peripheral edemaVascular disorders | 1/10 |
| Age, Categorical(Participants) | Treprostinil Sodium |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 8 |
| >=65 years | 2 |
| Sex: Female, Male(Participants) | Treprostinil Sodium |
|---|---|
| Female | 8 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Treprostinil Sodium |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Treprostinil Sodium |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Treprostinil Sodium |
|---|---|
| United States | 10 |
| PAH Etiology(participants) | Treprostinil Sodium |
|---|---|
| Idiopathic PAH | 7 |
| Connective Tissue Disease (CTD) | 2 |
| Other | 1 |
| World Health Organization (WHO) Functional Classification for PAH(participants) | Treprostinil Sodium |
|---|---|
| Class II | 6 |
| Class III | 4 |
| Six minute walk distance(meters) | Treprostinil Sodium |
|---|---|
| Mean | 447.7 (195 to 663) |
1 further baseline measures are reported on the registry.
The record gives a start of Sep 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 5 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil